These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
66 related articles for article (PubMed ID: 16842378)
1. Assessment of the validity of a population pharmacokinetic model for epirubicin. Ralph LD; Sandstrom M; Twelves C; Dobbs NA; Thomson AH Br J Clin Pharmacol; 2006 Jul; 62(1):47-55. PubMed ID: 16842378 [TBL] [Abstract][Full Text] [Related]
2. Maximum a posteriori Bayesian estimation of epirubicin clearance by limited sampling. Ralph LD; Thomson AH; Dobbs NA; Twelves C Br J Clin Pharmacol; 2004 Jun; 57(6):764-72. PubMed ID: 15151522 [TBL] [Abstract][Full Text] [Related]
3. A population model of epirubicin pharmacokinetics and application to dosage guidelines. Ralph LD; Thomson AH; Dobbs NA; Twelves C Cancer Chemother Pharmacol; 2003 Jul; 52(1):34-40. PubMed ID: 12764671 [TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years. Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734 [TBL] [Abstract][Full Text] [Related]
5. Plasma and tissue pharmacokinetics of epirubicin and Paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced primary breast cancer. Hunz M; Jetter A; Warm M; Pantke E; Tuscher M; Hempel G; Jaehde U; Untch M; Kurbacher C; Fuhr U Clin Pharmacol Ther; 2007 May; 81(5):659-68. PubMed ID: 17301739 [TBL] [Abstract][Full Text] [Related]
6. Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients. Sandström M; Lindman H; Nygren P; Johansson M; Bergh J; Karlsson MO Cancer Chemother Pharmacol; 2006 Aug; 58(2):143-56. PubMed ID: 16465545 [TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of raltitrexed in patients with advanced solid tumours. Blair EY; Rivory LP; Clarke SJ; McLachlan AJ Br J Clin Pharmacol; 2004 Apr; 57(4):416-26. PubMed ID: 15025739 [TBL] [Abstract][Full Text] [Related]
8. Epirubicin in patients with liver dysfunction: development and evaluation of a novel dose modification scheme. Dobbs NA; Twelves CJ; Gregory W; Cruickshanka C; Richards MA; Rubens RD Eur J Cancer; 2003 Mar; 39(5):580-6. PubMed ID: 12628836 [TBL] [Abstract][Full Text] [Related]
9. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. Zhou H; Mayer PR; Wajdula J; Fatenejad S J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and myocardial enzyme profiles of two administration routes of epirubicin in breast cancer patients. Yang RX; Ren HX; Zhuang L; Gao CL; Dong C; Luo CX; Wang XN; Feng EF; He JC Arzneimittelforschung; 2012 Dec; 62(12):677-81. PubMed ID: 23203544 [TBL] [Abstract][Full Text] [Related]
11. The influence of sparse data sampling on population pharmacokinetics: a post hoc analysis of a pharmacokinetic study of morphine in healthy volunteers. Ariano RE; Duke PC; Sitar DS Clin Ther; 2012 Mar; 34(3):668-76. PubMed ID: 22381713 [TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Bruno R; Washington CB; Lu JF; Lieberman G; Banken L; Klein P Cancer Chemother Pharmacol; 2005 Oct; 56(4):361-9. PubMed ID: 15868146 [TBL] [Abstract][Full Text] [Related]
13. An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity. Prado CM; Lima IS; Baracos VE; Bies RR; McCargar LJ; Reiman T; Mackey JR; Kuzma M; Damaraju VL; Sawyer MB Cancer Chemother Pharmacol; 2011 Jan; 67(1):93-101. PubMed ID: 20204364 [TBL] [Abstract][Full Text] [Related]
14. [Meta-analysis of the Italian studies on short-term effects of air pollution]. Biggeri A; Bellini P; Terracini B; Epidemiol Prev; 2001; 25(2 Suppl):1-71. PubMed ID: 11515188 [TBL] [Abstract][Full Text] [Related]
15. Multifactorial approach to predicting resistance to anthracyclines. Desmedt C; Di Leo A; de Azambuja E; Larsimont D; Haibe-Kains B; Selleslags J; Delaloge S; Duhem C; Kains JP; Carly B; Maerevoet M; Vindevoghel A; Rouas G; Lallemand F; Durbecq V; Cardoso F; Salgado R; Rovere R; Bontempi G; Michiels S; Buyse M; Nogaret JM; Qi Y; Symmans F; Pusztai L; D'Hondt V; Piccart-Gebhart M; Sotiriou C J Clin Oncol; 2011 Apr; 29(12):1578-86. PubMed ID: 21422418 [TBL] [Abstract][Full Text] [Related]
16. [Populational pharmacokinetics of doxorubicin applied to personalised its dosing in cancer patients]. Escudero-Ortiz V; Ramón-López A; Duart MA; Pérez-Ruixo JJ; Valenzuela B Farm Hosp; 2012; 36(4):282-91. PubMed ID: 22129650 [TBL] [Abstract][Full Text] [Related]
17. Serum pharmacokinetics in patients treated with transarterial chemoembolization (TACE) using two types of epirubicin-loaded microspheres. Sottani C; Poggi G; Quaretti P; Regazzi M; Montagna B; Quaquarini E; Imbriani M; Leoni E; Di Cesare P; Riccardi A; Bernardo G; Minoia C Anticancer Res; 2012 May; 32(5):1769-74. PubMed ID: 22593459 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients. Rezai K; Urien S; Isambert N; Roche H; Dieras V; Berille J; Bonneterre J; Brain E; Lokiec F Cancer Chemother Pharmacol; 2011 Dec; 68(6):1529-36. PubMed ID: 21519841 [TBL] [Abstract][Full Text] [Related]
19. Time of drug administration, CYP3A5 and ABCB1 genotypes, and analytical method influence tacrolimus pharmacokinetics: a population pharmacokinetic study. Musuamba FT; Mourad M; Haufroid V; Delattre IK; Verbeeck RK; Wallemacq P Ther Drug Monit; 2009 Dec; 31(6):734-42. PubMed ID: 19855314 [TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetic analysis of meropenem in Japanese adult patients. Muro T; Sasaki T; Hosaka N; Umeda Y; Takemoto S; Yamamoto H; Kamimura H; Higuchi S; Karube Y J Clin Pharm Ther; 2011 Apr; 36(2):230-6. PubMed ID: 21366653 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]